AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
US FDA approves AstraZeneca's Imfinzi for lung cancer treatment
The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
AstraZeneca's Imfinzi gets FDA priority review for type of lung cancer
AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.
Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs
In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—hitting all-time highs even as the broader market indices attempt to regain their footing.
AstraZeneca faces state funding blow at Merseyside project
AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the £450 million forecast to be spent to facilitate the site development, the former Tory government had promised to contribute £65 million.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.
AstraZeneca first London-listed company to surpass £200bn valuation
AstraZeneca PLC (LSE:AZN) has become the first UK-listed company to surpass a £200 billion stock market valuation after shares gained on Tuesday. Shares ticked up 1.2% to 12,928p throughout the day, leaving the pharmaceutical giant with a £200.02 billion valuation.
The Zacks Analyst Blog AstraZeneca, Ionis and Sanofi
AstraZeneca, Ionis and Sanofi are included in this Analyst Blog.
Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market
AstraZeneca's CEO has a vision for the weight loss drugs market. There probably won't be one medicine that's useful in every niche.
AstraZeneca falls after UK drug watchdog blocks NHS access to Enhertu drug
AstraZeneca PLC (LSE:AZN) shares fell more than 1.7% on Tuesday after the English healthcare watchdog said that it could not recommend the drug company's breast cancer drug for the NHS. The National Institute for Health and Care Excellence (Nice) said it was unable to recommend Enhertu for use in NHS England for advanced a common form of breast cancer, HER-2-low breast cancer.
AstraZeneca shows promise in phase III study
A new combination treatment has shown significant improvement in treating chronic lymphocytic leukaemia (CLL) in a recent clinical trial. The AMPLIFY Phase III study found that a fixed duration of AstraZeneca PLC's (LSE:AZN) Calquence (acalabrutinib) combined with venetoclax, with or without obinutuzumab, helped patients live longer without the disease getting worse, compared to the current standard chemotherapy.
